Allen Institute for Artificial Intelligence
supp.ai logo
supp.ai

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 2 years ago

Possible Interaction: Epinephrine and Physostigmine

supplement:

Epinephrine

Research Papers that Mention the Interaction

Cholinergic stimulation of the hypothalamic‐pituitary‐adrenal axis and adrenal medulla by physostigmine enhances secretion of arginine vasopressin, epinephrine , and norepinephrine.
Anesthesiology  •  1998  |  View Paper
Administration of physostigmine , unlike that of neostigmine, was associated with statistically significant increases in plasma concentrations of cortisol, prolactin, ACTH, beta-endorphin/beta-lipotropin-like immunoreactivity, and epinephrine , presumably via central mechanisms.
Psychoneuroendocrinology  •  1986  |  View Paper
Physostigmine promptly increased plasma arginine vasopressin (tenfold), beta-endorphin (twofold to threefold) and epinephrine (threefold) levels in elderly control subjects.
Archives of general psychiatry  •  1989  |  View Paper
A dose of 0.022 mg/kg physostigmine dramatically increased plasma epinephrine levels and slightly increased norepinephrine levels, which is consistent with selective adrenomedullary stimulation.
The Journal of clinical investigation  •  1984  |  View Paper
ConclusionsThese results suggest that physostigmine worsens ischemic outcome by a mechanism that is associated with increases in plasma epinephrine and norepinephrine.
ResultsCompared to control rats, physostigmine increased plasma epinephrine and norepinephrine 10-fold and worsened neurologic outcome.
Anesthesiology  •  1993  |  View Paper
Phenylephrine, adrenaline and dopamine markedly inhibited pressure responses to physostigmine , while the responses to acetylcholine were impaired to a less extent.
Scandinavian journal of gastroenterology. Supplement  •  1984  |  View Paper
The anticholinesterase physostigmine decreased hypothalamic epinephrine concentrations and this effect was blocked by the centrally acting nicotinic antagonist mecamylamine, but not by hexamethonium, scopolamine or methscopolamine.
The Journal of pharmacology and experimental therapeutics  •  1982  |  View Paper
Although physostigmine produced marked glycogenolysis in the control dogs it significantly inhibited cardiac glycogenolysis after light petroleum plus adrenaline , atrial glycogenolysis after strophanthin‐K‐induced arrhythmias and ventricular glycogenolysis after myocardial ischaemia.
British journal of pharmacology  •  1972  |  View Paper
Further, combined administration of adrenaline and physostigmine , both of which otherwise activated the heart enzyme, resulted in an inhibition of the enzyme activity.
Japanese journal of pharmacology  •  1965  |  View Paper